SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression[2].In Vitro: SRX3207 (10 μmol/L) is able to block p-AKT at concentration.
SRX3207 has sufficient solubility in water (43 μmol/L).In Vivo: SRX3207 (10 mg/kg, orally) increases antitumor immune response.